Literature DB >> 2447178

Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments.

P J Higgins1, H L Weiner.   

Abstract

We report that experimental autoimmune encephalomyelitis, a T cell-mediated autoimmune disease studied as a model for multiple sclerosis, can be suppressed in Lewis rats by the oral administration of myelin basic protein (MBP). Both the clinical and histopathologic manifestations of the disease were suppressed in a dose-dependent manner. In addition, proliferative responses to MBP and, to a lesser extent, serum levels of anti-MBP antibody were suppressed by feeding MBP. Suppression of clinical and histologic disease was observed whether animals were fed MBP before or after disease induction, although suppression was more complete when rats were fed before immunization. Disease was also suppressed by the oral administration of either encephalitogenic or nonencephalitogenic fragments and decapeptides of the MBP molecule, with more complete suppression observed when nonencephalitogenic fragments were fed, suggesting that suppressor determinants exist in the MBP molecule distinct from the encephalitogenic region. The oral administration of a non-disease-inducing portion of an autoantigen represents an antigen-specific method by which an experimental autoimmune disease can be immunoregulated.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2447178

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  81 in total

1.  Induction of hyporesponsiveness to intact foreign protein via retroviral-mediated gene expression: the IgG scaffold is important for induction and maintenance of immune hyporesponsiveness.

Authors:  Y Kang; M Melo; E Deng; R Tisch; M El-Amine; D W Scott
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

2.  T-cell activation occurs simultaneously in local and peripheral lymphoid tissue following oral administration of a range of doses of immunogenic or tolerogenic antigen although tolerized T cells display a defect in cell division.

Authors:  Karen M Smith; Joanne M Davidson; Paul Garside
Journal:  Immunology       Date:  2002-06       Impact factor: 7.397

Review 3.  Approaches toward peptide-based immunotherapy of autoimmune diseases.

Authors:  L Adorini; J C Guéry; S Trembleau
Journal:  Springer Semin Immunopathol       Date:  1992

Review 4.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

Review 5.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

6.  Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit.

Authors:  J B Sun; C Rask; T Olsson; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

7.  Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients.

Authors:  H Fukaura; S C Kent; M J Pietrusewicz; S J Khoury; H L Weiner; D A Hafler
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 8.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

9.  Continuous nasal administration of antigen is critical to maintain tolerance in adoptively transferred autoimmune arthritis in SCID mice.

Authors:  T Bárdos; M Czipri; C Vermes; J Zhang; K Mikecz; T T Glant
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 10.  Trials in type 1 diabetes: Antigen-specific therapies.

Authors:  Ken T Coppieters; Leonard C Harrison; Matthias G von Herrath
Journal:  Clin Immunol       Date:  2013-02-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.